Schering/Cor Therapeutics Integrilin reduces death/myocardial infarctions in PURSUIT trial.
SCHERING/COR INTEGRILIN REDUCES DEATH OR MI INCIDENCE IN UNSTABLE ANGINA in the Platelet IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial, M. L. Simoons, MD, Thoraxcenter (Rotterdam, the Netherlands), reported Aug. 25 at the European Society of Cardiology meeting in Stockholm. Therapy with Cor Therapeutics' Integrilin (eptifibatide) led to an absolute reduction in the incidence of death or re-infarction in unstable angina patients of 1.5% after 30 days.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth